drugset / Trial / NCT03301181

Phase 1 Study to Investigate Effect of Rifampin and Itraconazole on the Pharmacokinetics of BGB-3111 in Healthy Subjects

NCT03301181

Phase 1 Completed 40 enrolled BeiGene
Non-randomizedParallel-groupOpen-labelBasic science

Summary

Phase 1 study in healthy subjects to determine the effect of rifampin (Part A) or itraconazole (Part B) on the pharmacokinetics of BGB-3111

Timeline

Start
2017-09-18
Primary completion
2017-11-07
Completion
2017-11-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Itraconazole Small molecule 200 mg
Subject Rifampin Small molecule 600 mg
Subject Zanubrutinib Small molecule 80 mg Oral
Subject Zanubrutinib Small molecule 320 mg Oral

Indications

No indication recorded.